Table 3.

Relative treatment effects extracted from the network analysis

Control group (ASAQ)	PP analysis [OR (95% CI)]	ITT analysis [OR (95% CI)]
AL	2.44 (1.03–5.78)	1.25 (0.78–2.00)
ASATPG	12.24 (2.68–55.85)	3.15 (1.02–9.70)
ASCD	0.47 (0.10–2.00)	0.39 (0.14–1.15)
ASSP	1.21 (0.49–2.99)	0.98 (0.49–1.95)
DHPP	1.87 (0.83–4.18)	1.06 (0.67–1.69)

Each ACT (taken as reference) was compared with the efficacy of ASAQ (control group) on day 28. Quantifying heterogeneity and inconsistency were τ² = 0.0622 and I² = 10.8% (p = 0.3441) and τ² = 0.0289 and I² = 13.9% (p = 0.3254) for PP and ITT analysis, respectively. ACT artemisinin-based combination therapy, AL artemether-lumefantrine, ASAQ artesunate-amodiaquine, ASATPG artesunate-atovaquone-proguanil, ASCD artesunate-chlorproguanil-dapsone, ASSP artesunate-sulfadoxine-pyrimethamine, DHPP dihydroartemisinin-piperaquine, PP per-protocol, ITT intention-to-treat, OR odds ratio, CI confidence interval